reason report
noth last forev addit thought recent
bottom line despit week correct ad
background reiter recent downgrad
market perform issu highlight note includ
valuat catalyst flow develop risk recent aggress
guidanc manag overal regard stock
rel fairli price compar peer fundament first
abbvi price-to-earnings multipl trade in-lin peer consensu
estim come less line thu
eras tangibl upsid previous anticip second
see diminish flow signific pipelin catalyst
compar risk less reward event
anticip remain concern potenti safeti
risk key pipelin product upadacitinib rova-t third see
competit payer risk two domin product
humira imbruvica potenti safeti risk key pipelin product
upadacitinib rova-t final difficulti understand
investor begun accept forecast seem
optimist given mani uncertainti respect categori
one multitud market regulatori polit clinic
commerci event could jeopard forecast abbvi
manag mark year anniversari spin-out
independ pharmaceut busi abbott lab current
manag confound skeptic doubt busi
stay power valu receiv signific long-
term equiti compens valu creat mani
manag compens tripl valu
level would anticip stock price prevail last
summer enterpris valu one
largest pharmaceut compani industri trade
premium pure-play pharmaceut compani leader merck
compar larg cap biotech coverag estim abbvi
stock discount growth premium biopharma
compani perpetu seem unreason despit abbvi
recent sell-off post-earn spike reiter market
perform rate see downgrad note limit upsid huge
d/g market perform pt
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
price target stock rate market perform
success transit corpor ownership success independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil growth rate matur biotechnolog compani remain
depend singl franchis humira sale total sale
suggest us valuat still discount compar diversifi peer
us biosimilar settlement competitor mp appear reassur investor
fear biosimilar entri exagger invalid expect oncolog product
imbruvica venclexta becom signific product gener
revenu compani next-gener hcv regimen boost
market share consider declin market look compani array
promis late-stag clinic medicin oncolog inflamm metabol diseas
product contribut revenu growth unlik materi
dilut massiv headwind face biosimilar enter market compet
great last seven month
abbvi stock one top perform stock larg cap biopharma categori
sinc sinc juli stock gain compar return
btk nbi drg exhibit abbvi rel
perform sinc juli vs vs btk vs nbi
vs drg
initi out-performance follow septemb settlement mp
biosimilar humira resolut district court trial move expect
biosimilar launch us januari rather
previous consensu expect event stock continu perform
posit fourth quarter first month basi posit
clinic catalyst increas pipelin revenu expect manag also
unveil new long-term guidanc octob suggest multi-billion
dollar peak revenu estim multipl exist develop product includ imbruvica
us alon venclexta upadacitinib risankizumab
exhibit stock perform compar benchmark
abbvi multipl one lowest peer group consensu
ep compar peer averag minimum maximum sinc
stock perform last seven month larg driven long-term expect
humira patent cliff pipelin forecaststh chang view materi impact
near-term estim bid price due tax save announc
match increas ep estim left minim impact multipl result
chang long term outlook stock re-rat peer group averag near term
multipl prior discount close current abbvi price-to-earnings compar
peer averag minimum maximum peer averag gain
turn multipl period stock gain turn multipl exhibit
abbvi price-to-earnings discount especi compar lower growth potenti peer group
one tenet upgrad octob see note credit certainti
robust pipelin upgrad outperform pt believ discount
close respect becom premium trade higher multipl
merck roch sanofi gilead celgen
exhibit abbvi price-to-earnings compar peer specif timepoint
price-to-earnings multipl expand last seven month
biggest chang amongst peer group eight compani experienc multipl expans
degre seven peer experienc multipl contract exhibit
given superior perform period current multipl upper
group peer believ make valuat argument exist
previous stock
exhibit price-to-earnings multipl expans compar peer
consensu revenu ep estim increas significantli recent
month boost abbvi stock erod anoth opportun upsid
sinc upgrad outperform earli octob consensu revenu ep
estim increas basi longer humira patent protect long-term
manag guidanc late-stag pipelin product element provid tail-
weight benefit estim period risen substanti
estim period
revenu estim increas much
higher exhibit
exhibit chang lp revenu estim sinc
consensu revenu estim increas
exhibit
exhibit chang consensu revenu estim sinc
ep estim upward revis caus increas longev
humira exclus us lower tax guidanc base new us tax legisl
sinc ep estim increas
substanti higher exhibit
exhibit chang lp ep estim sinc
increas consensu ep estim sinc uniform
specif consensu ep estim increas
exhibit
exhibit chang consensu ep estim sinc
leerink estim modestli current consensu
revenu forecast significantli consensu follow
increas consensu revenu ep estim revenu forecast
in-lin slightli consensu period revenu estim
consensu line exhibit
exhibit lp revenu forecast relat consensu
likewis ep estim consensu line
exhibit ep differ could contract consensu model
incorpor new tax rate guidanc
exhibit lp ep forecast relat consensu
remain near-term catalyst modest like fulli
enter second half impress number near-term catalyst
offer meaning upsid stock price exhibit approv mavyret us
eu held promis particularli given potenti broad simpl label strong contract
perform upadacitinib phase readout rheumatoid arthriti immin
risankizumab psoriasi psoriat arthriti data offer potenti confirm profil
abbvi entrant venclexta murano trial offer platform significantli
increas expect less signific event rova-t triniti trial elagolix
regulatori file also immin major catalyst pass mostli
success price stock
investor uncertainti strength posit hcv
risankizumab profil less assur sever larg pivot trial readout
upadacitinib remain somewhat controversi view expect least
competit second gener jak inhibitor gilead mp lilli
mp elagolix approach commerci first indic although still face
question competit profil durat treatment overwhelmingli posit data
venclexta cll phase murano studi highlight strengthen investor
confid late stage hematology/oncolog pipelin
compar last month see rel meaning catalyst next month
investor pay close attent result trinti trial rova-t small cell lung
cancer expect readout alreadi delay
regard fda caution efficaci signal nervous drug alreadi
signific safeti concern earlier disclosur guid
treatment line achiev peak sale
remain near term event next month larg regulatori file
updat time pivot trial initi seem like move stock
materi compar event last six month inde recent financi
updat next step seem like financi rather clinic scientif
februari compani announc signific boost share repurchas program
dividend like prowl signific acquisit boost long
term outlook time-frame
exhibit list catalystscomplet versu near-term
abbvi charm posit humira like challeng
us sale abbvi humira exceed consensu expect peak us sale
peak us sale forecast peak us sale achiev
anti-tnf competitor remicad enbrel depend humira
either anti-tnf competitor ever op much
drugindicationtrialexpect time june eu regulatori result reg placebo dmard fibrosi cf albatross phase ii top-line risankizumabpsoriat arthritisphas iib immhanc phase trial cll combo w/ rituxanmurano phase abc-typ dlbclcombo w/ r-chopphoenix phase trial line r/r waldenstrom sphase trial phase ii trial updaterova-tsclctrin phase ii trial back tumorsbasket trial updateupadacitinibatop dermatitisphas iib trial fibroidsphas initi trial resultsy back comeupadacitinibatop dermatitisphas comeupadacitinibraresult remain phase comeupadacitinibrareg come risankizumabcrohn diseasephas come risankizumabulc colitisphas come risankizumabpsoriasisreg come risankizumabrareg comesourc leerink partner research compani report present clinicaltri gov abbvi inc
revenu concentr sales/ profit larg cap biotech vs celg
op mp mp
tnf competitor manag effect payer neg net
price revenu trend time humira continu maintain solid net price
power enbrel disclos end would need rebat net price
increas back payer order maintain formulari posit remicad launch
one biosimilar begin impact net price recent disclos price
reduct well signific revenu eros respons biosimilar competit
two competit product enbrel directli analog humira given similar
subcutan mode administr two product also close match gross
price therefor would expect net price product roughli similar
match level discount look past year im nation sale perspect
data captur invoic amount wholesal rebat discount
abl compar estim report sale calcul gross-to-net
discount product trend exhibit
find net price humira absolut higher enbrel
gap close payer pressur start mount industri
enbrel list price increas entir rebat payer estim gap
two product net price predict gap
two product might close larger discount less price power humira believ
trajectori toward flat neg net price like continu inevit affect
humira fact new competitor substitut see come market pressur
price share humira like intensifi
exhibit humira enbrel estim discount year
humira still face competit within outsid anti-tnf class
along potenti price competit humira also face market share competit new
brand entrant key therapeut area exhibit rheumatoid arthriti
earn us humira revenu humira posit secur major
drug class market decad treatment order specif
class entrench physician habit guidelin anti-tnf seem like remain
prefer biolog inject treatment captur longest patient
durat highest revenu overal critic question whether introduct
novel oral immunotherapi particularli jak inhibitor gilead filgotinib lilli baricitinib
disrupt flow patient inject immin fda review
baricitinib shed light agenc view role agent given
favor profil shown far gilead filgotinib distinct possibl even though
abbvi partial hedg share loss upadacitinib effect introduct
jak like net neg
situat even competit dermatolog new target mechan
action psoriasi launch past year dramat improv efficaci
eas use compar humira dermatolog repres humira us sale
sub-seg like face much competit pressur rheumatolog otezla
alreadi take share categori also expand market celgen
recent contract payer discount price allow use new biolog
class demonstr near doubl skin clearanc rate
compar humira also offer conveni extend dose interv far
increment efficaci conveni come signific advers event safeti
liabil reason seem inevit drug cosentyx taltz tremfya
abbvi risankizumab pressur humira revenu outlook indic
biggest threat humira forthcom competit gastroenterolog current
contribut us sale stelara antibodi launch late
experienc rapid uptak crohn diseas compar diseas indic humira
rel low efficaci ulcer coliti crohn patient frequent cycl though anti-
tnf surgeri fail achiev durabl diseas remiss leav ampl opportun
new medicin class launch disrupt market launch
jaki other like expand market steal share incumb anti-tnf
mostli humira sever therapi oral medicin like mani patient
prefer oral treatment option inject least initi given domin
indic today even potenti particip two differ option
upadacitinib risankizumab given number new entrant seem inevit humira
lose share also price absolut revenu indic inform
gastroenterolog market see inflammatori bowel diseas white paper futur
ibd categori doubl despit disappoint
exhibit list competit class humira therapeut area
competitor imbruvica like challeng innov supremaci cll
intensifi competit biopharmaceut industri becom import theme us
investor year impact issu blunt posit tailwind
tax reform influenc mean direct indirect competit
increas effect industri sentiment valuat
competit threat imbruvica chronic lymphocyt leukemia cll follow-on
btk inhibitor astrazeneca azn mp acalabrutinib calquenc known
time pivot trial data competit btk program
present acalabrutinib phase ii studi result mantel cell lymphoma mcl
decemb data gener btk inhibitor demonstr overal respons
complet respons surviv rate compar favor imbruvica relaps
refractori mantl cell lymphoma patient exhibit dataset still matur await
median month os result would enabl direct comparison
two trial result
meantim acalabrutinib obtain fda approv line mcl set
on-going pivot studi imbruvica key indic includ mcl cll prior
initi mcl data acalabrutinib investor question imbruvica domin posit
current indic sentiment seem like chang data readout
acalabrutinib next year importantli head head trial cll
convers lead hematolog oncolog physician follow suggest
doctor may keen switch imbruvica better toler btk inhibitor particularli
equival superior efficaci demonstr specialist spoke suggest
experi real differ acalabrutinib ibrutinib imbruvica term
safeti toler like result earli adopt patient increas risk
intoler imbruvica well pose long term threat imbruvica valu abbvi
certainli earli data mcl suggest acalabrutinib present seriou
competit imbruvica least indic see similar result cll would
substanti risk us revenu guidanc imbruvica
exhibit comparison imbruvica calquenc
one bigger event first pivot data rova-t result
small cell lung cancer sclc triniti trial previous delay month
base fda request extend durat follow initi respons
trial previou work suggest indic rel low bar success
trial would like posit opportun alreadi price consensu see note
loom rova-t sclc result catalyst triniti need orr os
fda delay inform rova-t profil concern
perhap initi respons seen trial proven durabl toxic
alreadi signific increas extend exposur drug
sinc guid peak revenu potenti rova-t multipl sclc treatment line
new indic compar peak forecast elev
import efficaci safeti come triniti readout abbvi total rova-t
revenu forecast materi higher current non-prob
success adjust forecast consensu result show shortfal
efficaci unaccept high rate seriou advers event complic credit
given acquisit evapor exhibit
drugmoaapprov indicationscompar efficaci mantl cellkey on-going studieskol feedbackimbruvicabtk mantl cell cll mzl gvhd wmorr mantl cell dlbcl life alter drug diarrhea rash afib gener btk mantl cellorr mantl cell cll vs imbruvica better drug improv toxic profil less toxic sourc fda gov leerink partner research abbvi inc
exhibit rova-t peak sale guidanc indic
origin plan releas triniti result push releas back
cite request longer durat follow fda specif
evp michael severino state request unusu develop
program single-arm studi use support approv statement
true call question safeti efficaci rova-t observ initi
data open-label trial rova-t antibody-drug conjug requir care
design safe deliv potent chemotherapi payload tumor site spare normal
tissu limit weak linkag could result increas safeti toler
issu safeti liabil unless fatal less issu avail
altern would diminish drug opportun earlier line well limit
phase studi rova-t report well-toler patient studi
found signific number advers event includ unusu one like attribut
tesirin toxic moieti antibody-drug conjug exhibit grade treatment-
emerg advers event teae report patient common
thrombocytopenia seros effus skin reaction studi also
report grade teae fatigu peripher edema combin
patient enrol studi patient discontinu rova-t due teae
result seros effus prior studi well one
consist signal increas pleural pericardi peripher fluid accumul
advers event could complic develop approv rova-t
refractori patient popul neg triniti result due safeti issu would
elimin peak consensu revenu remov upsid opportun catalyst
label expans would lower credibl busi develop team
indicationstudypeak sale sclcmeru i/o neuroendocrin tumorsbasket abbvi inc
abbvi import pipelin asset upadacitinib inhibitor inflammatori
diseas forecast global revenu risk-unadjust consensu
forecast global revenu guid sale
press releas present success phase result rheumatoid arthriti trial
efficaci drug consist impress howev report venou
thromboembol event vte includ pulmonari emboli pe deep vein thrombos
dvt placebo-control portion phase trial remain concern particularli
context lilli delay approv baricitinib certain disclosur upadacitinib
rel vs specif vte report publish
upadacitinib phase ii result vte crossov non placebo-control
portion select-beyond phase trial week week
concern investor sinc lilli receiv complet respons letter baricitinib fda
basi vte translat event rate per patient year exposur
clinic literatur suggest event rate per patient year typic
rheumatoid arthriti patient would appear consist observ rate
baricitinib studi nevertheless fda appear concern led complet
respons letter delay potenti approv recent research safeti entir
jak class includ post approv report mp xeljanz suggest
jak inhibit led vte would expect ra popul see note
aint worri jak safeti abbvi profil far ok
howev still present publish full result phase rheumatoid arthriti
trial patient heighten safeti signal put risk multi-billion peak
consensu forecast manag guidanc point previous even
vte event could result chang event rate could cross threshold
regulatori concern still believ upadacitinib promis drug also believ
risk label restrict direct rival gilead/galapago filgotinib last
public disclosur filgotinib case vte event entir develop
experi drug patient event rate per patient year although
larg inflammatori bowel diseas popul lower baselin vte risk
phase rheumatoid arthriti data releas date filgotinib also consist
lower platelet level rather increas wherea effect upadacitinib platelet
mix lower level lower dose flat slightli increas level higher
dose public thoroughli explor effect upadacitinib platelet
human studi manag publicli state drug led modest
decreas platelet level howev neg hematopoiet effect name decreas
hemoglobin level seen higher dose advanc upadacitinib
appear dose-depend loss select within therapeut window
vte associ inhibit baricitinib inhibit greater extent xeljanz
primarili upadacitinib suggest vivo dose-depend inhibit may
liabil drug either larger clinic trial subject increas regulatori
lack specif upadacitinib corrobor pre-clin studi fund
develop baricitinib lilli op intern data suggest
upadacitinib specif higher cellular assay
higher whole blood assay signal gmcsf signal analysi
peripher blood mononuclear cell pbmc collect healthi donor use
assay estim plasma concentr product phase dose dose
jak inhibitor develop analysi provid drug drug dose-respons curv
stat inhibit measur inhibit downstream phosphoryl stat protein
cytokin dose respons curv investig
establish half maximum inhibitori concentr requir drug
phosphoryl gm-csf cytokin signal good marker
specif result suggest upadacitinib potent inhibitor
signal compar baricitinib filgotinib upadacitinib also potent inhibitor
compar filgotinib equal potenc baricitinib specif upadacitinib
approxim compar baricitinib filgotinib
higher upadacitinib exhibit given daili dose
studi develop investig estim highest dose would
inhibit upadacitinib hour day wherea
baricitinib would inhibit day filgotinib day
even importantli rel gm-csf
upadacitinib wherea baricitinib filgotinib studi
conduct sponsor lilli therefor subject liabil bias
company-sponsor research howev studi suggest dimens least
filgotinib might best profil baricitinib somewher
exhibit rel jak inhibitor stat phosphoryl
long term forecast manag seem best case scenario
earn present manag surpris us investor
provid new long-term revenu guidanc key product us alon
venclexta upadacitinib risankizumab elagolix also
highlight peak sale opportun rova-t indic treatment line
exceed total final disclos non-humira revenu would reach
risk-adjust basi nomin basi market react posit
releas extra help us tax reform stock perform sinc
date howev neither estim consensu reach manag forecast fact
even remov probabl success po adjust forecast
abbvi forecast consider model exhibit hard reconcil
larg differ revenu outlook particularli sinc still year away multitud
new and/or transform medicin treatment could emerg time industri
price payment environ could also substanti alter date find hard
understand logic offer forecast first place given uncertainti
industri categori fundament find difficult get
individu product forecast optimist scenario competitor fail
develop commerci
exhibit abbvi guidanc compar leerink consensu
stock perform friday januari incorpor correct
week januari find stock trade premium ebitda
multipl larg cap biotech peer trade similarli high growth compani like
alexion regeneron larg cap biopharma compani even diversifi
pharmaceut compani exhibit specif abbvi ebitda multipl
multipl larg cap biotech compani rang averag
discrep attribut lower tax rate allow
ebitda flow free cash flow larg cap biopharma peer portion
premium also attribut growth expect indic compani manag
believ realist achiev
exhibit ebitda multipl comparison biotech peer
abbvi multipl also longer significantli discount us european pharmaceut
peer equival averag multipl group exhibit price-to-earnings
multipl diversifi pharma compani longer tail valu still turn
believ fundament deserv premium multipl compar
averag group
estimatesimbruvica usvenclexta globalupadacitinib globalrisankizumab globalelagolix globalnon-humira -global manag po po ebitda multipl comparison absolut discount discount larg capsemerg larg cap abbvi inc
consensu revenu multiplespric cap mm price salespric salespric salespric salespric salesproject sale price sales/ cap ep multiplespric cap mm price epspric epspric epspric epspric epsproject ep cap abbvi inc
altern dcf suggest would need grow perpetu
incorpor tax rate differenti biotech peer better contextu
ebitda multipl discrep built simpl dcf model assum payment ebitda
multipl biotech ebitda begin
perpetu factor superior tax rate cash flow calcul
solv growth rate requir npv equal discount wacc
assumpt note increas tax rate effect gilti tax rate
increas suscept foreign intang incom us tax increas
use approach found justifi premium stock
investor must believ grow faster rest biotech perpetu
achiev equival present valu cash flow exhibit word need
grow biotech peer forev current ebidta multipl stock price
ration invest recent trade level
exhibit dcf scenario solv growth rate requir multipl
recommend would signal compani largest
biopharma compani exist
stock doubl last year multipl
premium rather discount peer biopharma compani fail see suffici upsid
justifi continu outperform rate fact maintain outperform rate standard
upsid stock current price would impli invest thesi predict would
becom close valuabl larg cap biopharma compani market cap enterpris
valu despit lower revenu peer exhibit growth
rate today strongest amongst peer concentr revenu product legaci
busi unit also highest humira patent cliff mean current growth
rate unsustain beyond believ long-term
fundament support premium content given disclos far
portfolio pipelin
exhibit suggest outperform upsid valuat compar pharma
manag incent appear align recent stock price
form januari predecessor compani abbott spun
research-bas pharmaceut busi time stock becam list
independ manag compens becam tie perform rather
abbott prior abbott unvest option convert option would
expect manag compens salari annual bonu longer
term equity-rel incent includ nonqualifi stock option restrict stock award
restrict stock unit rsu time spin-out stock program reserv
share stock employe compens grant
manag prior spin
manag stock option year life vest one-third increment three
year period thu origin grant fulli vest replac recur annual
stock grant weight averag exercis price option grant time spin
unrecogn compens stock option time spin
restrict stock award grant time spin-out vest year rsu
vest year fair valu rsa rsu decemb time
spin unrecogn futur rsa rsu expens period
even year spin-out valu initi
subsequ grant rel modest
shortli spin senior manag receiv larg grant restrict stock
unit rsu five year vest februari grant amount
rsu ceo gonzalez cfo compar larg grant
senior execut time final vest larg post-spin grant februari
current stock price senior manag also grant larg stock option
grant time vest ratabl three year initi grant
compens analysi subject consider uncertainti prior vest equiti
exercis vs held condit amount prior vest analysi still suggest
abbvi senior execut signific stake valu compani stock
interest valu appear tie stock perform februari year sinc
time vest prior year equiti grant well grant new equiti
importantli prior period rsu particularli year vest
import vest mileston grant well
overal seem compens polici align sharehold interest
least term currenc use compens equiti vs cash longer term vs shorter
term nevertheless given import equiti compens compon
manag long term compens execut pay long term equity-link
incent fact much prior period equiti vest februari year
imposs believ manag particularli attent share
price perform month februari attent may heighten year
given equiti compon year vest end long term
option convert abbott expir year usual vest recent period stock
option grant februari year given previous tepid share price perform
interest like heighten year
exhibit long-term incent compens abbvi
elementeventtiming/scop eventincent simplifi grantannu rsu grant effect share price maxim valu prior period grantsgrantannu option grant made option fulli vest abbott carryov option expiri stock price mandatori exercis expir optionsbetween prior year rsu vest februari price maxim number grant materi stockhold maxim price maxim valu vest option prior grantsminim share price time grant maxim ultim value/unitrsu soption abbvi inc
exhibit compens histori name execut post-spin summari
def file leerink analysi
name execut offic titl current ageabbottabbvi gonzalez ceo yearnanarsu yearnanaequ grant grant vest cfo yearnanarsu yearnanaequ grant grant vest schumach evp counsel yearnanarsu yearnanaequ grant grant vest per option mid per option today abbvi inc
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk rhhbi sni nv celg
averag consensu ep multipl appli current ep estim
give valu use revenu multipl similar
compani consensu sale appli revenu estim
give valu lastli dcf valuat given wacc
termin cash flow growth rate begin humira biosimilar entri give
present valu averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin increas current level
toward fail reach sustain level would advers affect
forecast valuat also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
mid-term growth tail risk nv azn celg
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
